Table 2.
List of miRNAs associated with AIC from previous studies in different models
miRNA | Model | Sample | Anthracyclines type | Regulation | Putative target pathway | References |
---|---|---|---|---|---|---|
miR‐17‐5p | Human | Blood | EC‐D | Down | Not reported | 74 |
miR‐210 | Human | Blood | EC‐D | Down | Not reported | 74 |
let‐7a | Human | Plasma | DOX | Up | Not reported | 49 |
let‐7f | Human | Blood | EC‐D | Down | Not reported | 74 |
let‐7f‐2‐3p | Cell lines | Cardiomyocytes | DOX | Up | Long noncoding RNA NEAT1 inhibits XPO1‐mediated HAX‐1 nuclear export | 75 |
Let‐7g | Rat | Heart tissue | DOX, L‐DOX | Down | Not reported | 76, 77 |
miR‐1 | Human/rat/mice | Plasma/heart tissue | DOX | Up | Not reported | 50, 78, 79 |
miR‐1 | Cell lines | Cardiomyocytes from treated animals | Epirubicin | Down | Suppress the PI3K/AKT/mTOR and NF‐κB signalling pathways | 80 |
miR‐122‐5P | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐125 | Human | Plasma | DOX | Up | Not reported | 49 |
miR‐126‐3p | Human | Plasma | Epirubicin | Up | Not reported | 48 |
miR‐127‐3p | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐1303 | Cell lines | Cardiomyocytes | DOX | Down | Not reported | 82 |
miR‐130a | Cell lines | Cardiac cells | DOX | Up | Apoptosis pathway | 83 |
miR‐133a | Rat, mice | Plasma | DOX | Up | Not reported | 78, 84 |
miR‐133a‐3p | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐133a‐3p | Mice | Plasma | DOX | Up | Not reported | 85 |
miR‐133b | Mice/human | Plasma | DOX | Up | Not reported | 50, 84 |
miR‐1‐3p | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐140‐3p | Mice | Plasma | DOX | Down | Not reported | 85 |
miR‐140‐5p | Rat/mice | Heart tissue | DOX | Up | Mitochondrial apoptosis, oxidative stress | 86, 87 |
miR‐143 | Human | Plasma | DOX | Down | Not reported | 49 |
miR‐145 | Human | Plasma | DOX | Up | Not reported | 49 |
miR‐146a | Human | Plasma | DOX | Up | Not reported | 50 |
miR‐146a | Rat | Neonatal rat cardiac myocytes | DOX | Up | ErbB4 | 88 |
miR‐146a | Cell lines | (hPSC‐CM) | DOX | Down | MMPs via the Fos/AP‐1 pathway | 89 |
miR‐15b | Cell lines | (hPSC‐CM) | DOX | Down | TGFβ‐pathway | 89 |
miR‐15b‐5p | Rat | Cardiomyocytes from treated animals | DOX | Up | Apoptosis, oxidative stress, and mitochondria damage | 90 |
miR‐182‐5p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐187‐3p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐191 | Human | Plasma | DOX | Up | Not reported | 49 |
miR‐199a‐3p | Human | Plasma | Epirubicin | Up | Not reported | 48 |
miR‐1a | Mice | Plasma | DOX | Up | Not reported | 84 |
miR‐200c | Mice | Heart tissue | DOX | Up | Zinc finger E‐box | 91 |
miR‐206 | Rat | Plasma | DOX | Up | Not reported | 78 |
miR‐208a | Rat | Heart tissue | DOX, L‐DOX | Down | Myosin heavy chain expression | 76 |
miR‐208a | Mice | Heart tissue | DOX | Up | GATA4 | 92 |
miR‐208a | Human | Plasma | DOX | Not released | Not reported | 93 |
miR‐208b | Rat | Rat heart | DOX | Up | Not reported | 94 |
miR‐20a | Human | Blood | EC‐D | Down | Not reported | 74 |
miR‐21 | Mice | Heart tissue | DOX | Up | Not reported | 79, 95 |
miR‐21 | Rat/mice | Mouse heart tissues and rat H9C2 cardiomyocytes | DOX | Up | B cell translocation gene 2 | 96 |
miR‐21 | Human | Plasma | DOX | Down | Not reported | 49 |
miR‐215 | Rat | Rat heart | DOX | Up | Not reported | 94 |
miR‐215‐5p | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐216b | Rat | Rat heart | DOX | Up | Not reported | 94 |
miR‐23a | Rat | Primary neonatal rat ventricular myocytes | DOX | Up | PGC‐1α/p‐Drp1, thereby inhibiting mitochondria‐dependent apoptosis | 97 |
miR‐29b | Rat | Heart tissue | DOX | Down | Mitochondria‐dependent pathway by directly targeting Bax | 98 |
miR‐29b | Human | Plasma | Anthracycline | Up | Not reported | 51 |
miR‐30 | Rat | Cardiomyocytes from treated animals | DOX | Down | Pro‐apoptotic gene BNIP3L/NIX | 99 |
miR‐30a | Rat | Cardiomyocytes from treated animals | DOX | Up | Autophagy in a miR‐30e/beclin‐1 signal pathway | 100 |
miR‐30e | Rat | Cardiomyocytes from treated animals | DOX | Up | Autophagy in a miR‐30e/beclin‐1 signal pathway | 100 |
miR‐301b‐3p | Mice | Plasma | DOX | Up | Not reported | 85 |
miR‐30c | Rat | Cardiomyocytes from treated animals | DOX | Up | Autophagy in a miR‐30e/beclin‐1 signal pathway | 100 |
miR‐320a | Mice | Heart tissue | DOX | Up | Not reported | 101 |
miR‐32‐5p | Mice | Plasma | DOX | Up | Not reported | 85 |
miR‐339 | Mice | Plasma | DOX | Down | Not reported | 84 |
miR‐34a | Mice, rat/cell lines | Plasma, heart tissue/(hPSC‐CM) | DOX | Up | Not reported | 84, 89, 102, 103 |
miR‐34a‐3p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐34a‐5p | Mice/rat | Cardiomyocytes/plasma | DOX | Up | Not reported | 81, 85, 104 |
miR‐34a‐5p | Human | Plasma | Epirubicin | Up | Not reported | 48, 104 |
miR‐34b‐3p | Mice | Plasma | DOX | Up | Not reported | 85 |
mir‐34c | Rat | Rat heart | DOX | Up | Not reported | 94 |
miR‐34c‐3p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐34c‐5p | Mice/cell lines | Plasma/cardiomyocytes | DOX | Up | Not reported | 82, 85 |
miR‐361 | Human | Plasma | DOX | Down | Not reported | 49 |
miR‐367 | Rat | Rat heart | DOX | Up | Not reported | 94 |
miR‐378 | Human | Blood | EC‐D | Down | Not reported | 74 |
miR‐423‐5p | Human | Plasma | DOX/epirubicin | Up | Not reported | 48, 50 |
miR‐431‐5p | Mice | Plasma | DOX | Down | Not reported | 85 |
miR‐4423‐3p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐451a | Mice | Plasma | DOX | Down | Not reported | 85 |
miR‐455‐3‐p | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐486‐3p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐486‐5p | Cell lines | Cardiomyocytes | DOX | Up | Not reported | 82 |
miR‐499 | Human | Plasma | Anthracycline | Up | Not reported | 51 |
mir‐499‐5p | Mice | Plasma | DOX | Up | Not reported | 85 |
miR‐499a‐5p | Mice | Plasma | DOX | Down | Not reported | 81 |
miR‐500a‐3p | NA | Cardiomyocytes | DOX | Down | Not reported | 105 |
miR‐532‐3p | NA | Cardiomyocytes | DOX | Up | Not reported | 105 |
miR‐532‐3p | Mice | Mice heart and cardiomyocytes | DOX | Up | Mitochondrial fission and apoptosis | 106 |
miR‐6236 | Mice | Plasma | DOX | Down | Not reported | 84 |
miR‐6240 | Mice | Plasma | DOX | Down | Not reported | 84 |
miR‐6946 | Mice | Plasma | DOX | Down | Not reported | 84 |
miR‐7058 | Mice | Plasma | DOX | Up | Not reported | 84 |
miR‐93‐5p | Mice | Plasma | DOX | Down | Not reported | 85 |
AIC, anthracycline‐induced cardiotoxicity; Akt, protein kinase B; AP‐1, Activator protein 1; BAX , Bcl‐2 Associated X‐protein; BNIP3L, BCL2 Interacting Protein 3 Like; DOX, doxorubicin; EC‐D, epirubicin/cyclophosphamide followed by docetaxel; Erb‐B2, Receptor Tyrosine Kinase 4; GATA4, GATA Binding Protein 4; HAX1, HCLS1 Associated Protein X‐1; hPSC‐CM, human induced pluripotent stem cell‐derived cardiomyocytes; MHC, major histocompatibility complex; miRNA, microRNA; MMPs, Matrix metallopeptidases; mTOR, The mammalian target of rapamycin; NEAT1, Nuclear Enriched Abundant Transcript 1; NF‐κB, Nuclear factor kappa B; PI3K, Phosphoinositide 3‐kinase; PGC‐1α, coactivator 1‐alpha; TGFβ, Transforming growth factor beta; XPO1, Exportin 1.